Chondrosarcomas are a heterogeneous group of malignant bone tumors that share in common the production of chondroid (cartilaginous) matrix. Doxorubicin, cisplatin, high-dose methotrexate and ifosfamide have antitumor activity in osteosarcoma, a similar type of cancer. Doxorubicin and cisplatin are frequently used as the basis of treatment, and there is evidence that combinations with methotrexate and/or ifosfamide might provide additional benefit over two-drug schedules. A variety of pre- and postoperative combinations are used in common practice and in clinical trials, and the ideal combination scheme and the optimal treatment duration are yet to be defined.NCCN does nto rpesent any chemo options for chondrdrosarcoma except for the dedifferentiated group, where it recommends treatment as osteosarcoma (CHON-1). It makes it explicit on p. BINE-C that there are no standard options. For the dedifferentiated type, it lists a variety of first and second line options but not CAV.
P. C. W. Hogendoorn and On behalf of the ESMO/EUROBONET Working Group Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol (2010) 21 (suppl 5): v204-v213.